NovoSLpeps

We are currently developing a first-of-its-kind, intranasally administered immunotherapy that uses a cocktail of peptides to stimulate the immune system to recognize mutated proteins expressed by the tumor cells or the tumor stroma. By leveraging an AI-driven algorithm, we will match a patient's HLA type with a curated library of 60-80 synthetic long peptides, creating a personalized combination designed to elicit a robust immune response.